Natera, Inc. Royalty — Deferred Revenue decreased by 64.3% to $500.00K in Q4 2025 compared to the prior quarter.
An increase suggests higher future revenue recognition potential from existing royalty contracts, while a decrease indicates that the company is fulfilling its obligations and recognizing the revenue.
This metric represents the deferred revenue or contract liability arising from royalty-based arrangements where the comp...
Comparable to deferred revenue or contract liabilities in other life sciences or biotech firms with significant intellectual property licensing models.
ntra_segment_royalty_contract_with_customer_liability| Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|
| Value | $1.20M | $1.40M | $500.00K |
| QoQ Change | — | +16.7% | -64.3% |
| YoY Change | — | +16.7% | -64.3% |